Showing 6721-6730 of 8823 results for "".
- Lumenis to be Acquired by XIOhttps://practicaldermatology.com/news/lumenis-to-be-acquired-by-xio/2458924/
- KYTHERA Biopharmaceuticals Announces FDA Approval of KYBELLA(TM) (also known as ATX-101) -- First and Only Submental Contouring Injectable Drughttps://practicaldermatology.com/news/kythera-biopharmaceuticals-announces-fda-approval-of-kybellatm-also-known-as-atx-101-first-and-only-submental-contouring-injectable-drug/2458953/KYTHERA Biopharmaceuticals, Inc. (Nasdaq:
- Provectus Biopharmaceuticals' Novel Synthesis Patent Application Allowed by Chinese Patent Officehttps://practicaldermatology.com/news/provectus-biopharmaceuticals-novel-synthesis-patent-application-allowed-by-chinese-patent-office/2459017/Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company (
- Dermira and UCB Announce Start of Phase 3 Program for Cimzia® (Certolizumab Pegol) in Psoriasishttps://practicaldermatology.com/news/dermira-and-ucb-announce-start-of-phase-3-program-for-cimzia-certolizumab-pegol-in-psoriasis/2459027/Dermira, Inc., a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients (NASDAQ: DERM), and UCB, a global biop
- CMS Assigns Q-code to Fish Skin Technology, Kerecis Reportshttps://practicaldermatology.com/news/20141113-cms_assigns_q-code_to_fish_skin_technology_kerecis_reports/2459065/The new Omega3 tissue-regeneration material from Kerecis Limited—dubbed fish skin—has received a "Q" code from the Centers for Medicare and Medicaid Services (CMS). Kerecis Omega3 Wound, indicated for the management of chronic wounds including diabetic, vascular and other hard-to-heal wounds, has b
- Syneron Candela Announces FDA Clearance of PicoWay Picosecond Laser for Tattoo Removalhttps://practicaldermatology.com/news/20141103-syneron_candela_announces_fda_clearance_of_picoway_picosecond_laser_for_tattoo_removal/2459076/The FDA granted 510(K) clearance to Syneron Candela's PicoWay picosecond device for tattoo removal. PicoWay is a dual wavelength device, with 1064nm and 532nm wavelengths, which utilizes the proprietary PicoWay Technology to generate picosecond pulses for the removal of tattoos. The FDA clearanc
- SKINPACT Program Launched with New Global Awards Initiative to Support the Dermatology Communityhttps://practicaldermatology.com/news/20141010-skinpact_program_launched_with_new_global_awards_initiative_to_support_the_dermatology_community/2459088/Galderma, in partnership with the International League of Dermatological Societies, has started a search for initiatives that will fulfill an important role in strengthening the global dermatology community. Galderma launched a new global initiative un
- Galderma Initiates US Study of Novel Muscle Relaxant for Aesthetic Dermatology and Cosmetic Surgeryhttps://practicaldermatology.com/news/20141006-galderma_initiates_us_study_of_novel_muscle_relaxant_for_aesthetic_dermatology_and_cosmetic_surgery/2459095/Galderma has initiated a Phase II clinical trial of a novel muscle relaxant in the US. The Phase II clinical trial is a multicenter, dose-ranging study designed to evaluate the safety and effectiveness of Galderma's internally developed liquid form of botulinum toxin for the tre
- Promius Pharma, LLC: Finalist for PM360 Company of the Year Awardhttps://practicaldermatology.com/news/20140828-promius_pharma_llc_finalist_for_pm360_company_of_the_year_award/2459136/Promius Pharma, LLC has been named as a Trailblazer Company of the Year finalist by PM360, a publication that covers the pharmaceutical, biotech and medical device industries. Promius is one of three finalists in the category of Company of the Y
- Trevi Therapeutics Announces the Issuance of Two Patents for Oral Sustained Release Formulation of Nalbuphine ERhttps://practicaldermatology.com/news/20140815-trevi_therapeutics_announces_the_issuance_of_two_patents_for_oral_sustained_release_formulation_of_nalbuphine_er/2459144/Trevi Therapeutics, Inc. received two issued U.S. patents with claims protecting the oral sustained release formulation of nalbuphine. The patent numbers are 8,771,732 and 8,765,175. The Company believes that both of these patents will be Orange Book-li